Effects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder

[1]  L. Siever,et al.  Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PET study with [11C]NNC112 , 2014, Psychopharmacology.

[2]  M. Egan,et al.  Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia , 2013, Schizophrenia Research.

[3]  D. Velligan,et al.  Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia , 2012, Schizophrenia Research.

[4]  Daniel C. Javitt,et al.  A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia , 2011, Biological Psychiatry.

[5]  J. Lieberman,et al.  Characterization of in vivo Pharmacokinetic Properties of the Dopamine D1 Receptor Agonist DAR-0100A in Nonhuman Primates Using PET with [11C] NNC112 and [11C] Raclopride , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  Philip D. Harvey,et al.  Pergolide Treatment of Cognitive Deficits Associated with Schizotypal Personality Disorder: Continued Evidence of the Importance of the Dopamine System in the Schizophrenia Spectrum , 2010, Neuropsychopharmacology.

[7]  Philip D. Harvey.  Pharmacological Cognitive Enhancement in Schizophrenia , 2009, Neuropsychology Review.

[8]  Kenneth M. Johnson,et al.  Activation of dopamine D1 receptors blocks phencyclidine‐induced neurotoxicity by enhancing N‐methyl‐D‐aspartate receptor‐mediated synaptic strength , 2009, Journal of neurochemistry.

[9]  Xuechu Zhen,et al.  Dopamine D1 receptor ligands: Where are we now and where are we going , 2009, Medicinal research reviews.

[10]  Philip D. Harvey,et al.  Context processing in schizotypal personality disorder: evidence of specificity of impairment to the schizophrenia spectrum. , 2008, Journal of abnormal psychology.

[11]  R. Keefe.  Cognitive deficits in patients with schizophrenia: effects and treatment. , 2007, The Journal of clinical psychiatry.

[12]  R. Mailman,et al.  A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia , 2007, Schizophrenia Research.

[13]  R. Mailman.  GPCR functional selectivity has therapeutic impact. , 2007, Trends in pharmacological sciences.

[14]  R. Mailman,et al.  A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia , 2007, Schizophrenia Research.

[15]  Danielle L. Graham,et al.  Differential ability of D1 and D2 dopamine receptor agonists to induce and modulate expression and reinstatement of cocaine place preference in rats , 2007, Psychopharmacology.

[16]  Michael F. Green,et al.  Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. , 2006, The Journal of clinical psychiatry.

[17]  B. Kull,et al.  Dihydrexidine--the first full dopamine D1 receptor agonist. , 2006, CNS drug reviews.

[18]  M. Williams,et al.  Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. , 2006, CNS drug reviews.

[19]  L. Siever,et al.  Neuropsychological performance in schizotypal personality disorder: importance of working memory. , 2005, The American journal of psychiatry.

[20]  C. Wahlestedt,et al.  A 68930 and dihydrexidine inhibit locomotor activity and d-amphetamine-induced hyperactivity in rats: a role of inhibitory dopamine d1/5 receptors in the prefrontal cortex? , 2004, Neuroscience.

[21]  R. Mailman,et al.  Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. , 2004, Molecular pharmacology.

[22]  Patricia S. Goldman-Rakic,et al.  Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction , 2004, Psychopharmacology.

[23]  Anissa Abi-Dargham,et al.  Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us? , 2003, World psychiatry : official journal of the World Psychiatric Association.

[24]  L. Siever,et al.  Neuropsychological performance in schizotypal personality disorder: evidence regarding diagnostic specificity , 2002, Biological Psychiatry.

[25]  R. Mailman,et al.  Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. , 2002, The Journal of pharmacology and experimental therapeutics.

[26]  R. Mailman,et al.  Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. , 2002, The Journal of pharmacology and experimental therapeutics.

[27]  R. V. Van Heertum,et al.  Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia , 2002, The Journal of Neuroscience.

[28]  R. Mailman,et al.  Parkinson's disease and D1 dopamine receptors. , 2001, Current opinion in investigational drugs.

[29]  P. Blanchet,et al.  Effects of the Full Dopamine Dl Receptor Agonist Dihydrexidine in Parkinson's Disease , 1998, Clinical neuropharmacology.

[30]  D. Hodges,et al.  D1 Agonist Dihydrexidine Releases Acetylcholine and Improves Cognitive Performance in Rats , 1997, Pharmacology Biochemistry and Behavior.

[31]  L. Siever,et al.  D-amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder , 1996, Schizophrenia Research.

[32]  D E Nichols,et al.  Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping. , 1996, Journal of medicinal chemistry.

[33]  D. E. Nichols,et al.  Spare receptors and intrinsic activity: Studies with D1 dopamine receptor agonists , 1995, Synapse.

[34]  M. Michaelides,et al.  (5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431). , 1995, Journal of medicinal chemistry.

[35]  R. Mailman,et al.  “Full” dopamine D1 agonists in human caudate: Biochemical properties and therapeutic implications , 1995, Neuropharmacology.

[36]  J. Schneider,et al.  Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys , 1994, Brain Research.

[37]  P. Goldman-Rakic,et al.  Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys , 1994, Psychopharmacology.

[38]  R. Mailman,et al.  Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist. , 1994, Journal of medicinal chemistry.

[39]  R. Mailman,et al.  Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents. , 1993, European journal of pharmacology.

[40]  R. Mailman,et al.  Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. , 1992, The Journal of pharmacology and experimental therapeutics.

[41]  R. Mailman,et al.  Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist. , 1991, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[42]  R. Mailman,et al.  trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. , 1990, Journal of Medicinal Chemistry.

[43]  R. Mailman,et al.  Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist. , 1989, European journal of pharmacology.

[44]  J. Kebabian,et al.  Multiple receptors for dopamine , 1979, Nature.

[45]  P. Spano,et al.  Dopamine receptors: pharmacological and anatomical evidences indicate that two distinct dopamine receptor populations are present in rat striatum. , 1978, Life sciences.

[46]  H. Sarau,et al.  The central effects of a novel dopamine agonist. , 1978, European journal of pharmacology.

[47]  Philip D. Harvey,et al.  Effects of Amphetamine on Visuospatial Working Memory Performance in Schizophrenia Spectrum Personality Disorder , 2000, Neuropsychopharmacology.

[48]  P. Goldman-Rakic.  Working memory dysfunction in schizophrenia. , 1994, The Journal of neuropsychiatry and clinical neurosciences.